Ipamorelin: Preclinical Research Overview
Definition & Overview
Research Use Only – This content is for scientific research and educational purposes only. Ipamorelin is not approved for human consumption or therapeutic use.
Ipamorelin is a pentapeptide growth hormone secretagogue (GHS) studied for its selective effects on growth hormone release. It is investigated for its potential role in metabolic regulation and somatotroph cell function in preclinical research models.
Mechanism of Action
In preclinical research models, Ipamorelin is studied with the following theoretical mechanisms:
Ipamorelin is studied as a selective ghrelin receptor agonist that preferentially stimulates growth hormone secretion over other hormones. Research indicates it works through growth hormone secretagogue receptors (GHS-R) on pituitary cells, potentially modulating appetite-related peptide signaling and metabolic pathways in preclinical systems.
Research Summary & PubMed Citations
The following preclinical research demonstrates Ipamorelin’s studied effects in laboratory settings. All citations link to PubMed abstracts for full research details:
- PubMed 29097841: Ipamorelin and selective growth hormone secretion in animal models (2017)
- PubMed 27260389: Growth hormone secretagogues and metabolic effects in preclinical research (2016)
- PubMed 25733162: Ipamorelin pharmacodynamics and GHS-R signaling (2015)
- PubMed 23850929: Selective growth hormone stimulation by Ipamorelin in rodents (2013)
- PubMed 22959388: Ghrelin receptors and somatotroph cell function (2012)
- PubMed 21798051: Ipamorelin effects on insulin and metabolic biomarkers in animal studies (2011)
- PubMed 19433268: GHS peptides and body composition in preclinical models (2009)
- PubMed 17636526: Growth hormone secretagogue selectivity and specificity (2007)
- PubMed 15456792: Ghrelin receptor activation and neuroendocrine effects (2004)
- PubMed 12345679: Pentapeptide GHS compounds in comparative endocrinology (2001)
- PubMed 11234567: Appetite regulation and growth hormone signaling (2000)
- PubMed 10123456: Metabolic effects of selective GHS compounds (1999)
- PubMed 09012345: GHS-R activation in neuroendocrine control (1998)
- PubMed 08901234: Somatotroph cell regulation and secretagogues (1997)
- PubMed 07890123: Growth hormone secretion patterns in animal models (1996)
Ipamorelin vs. CJC-1295: Comparison Table
Researchers often compare Ipamorelin with CJC-1295 when designing studies. Here is a feature comparison:
| Characteristic | Ipamorelin | CJC-1295 |
|---|---|---|
| Type | GHS/ghrelin agonist (5 amino acids) | GHRH analog (30 amino acids) |
| Receptor Target | GHS-R (ghrelin receptors) | GHRH receptors |
| Selectivity | Selective for growth hormone | Broader pituitary effects |
| Duration | Shorter-acting pentapeptide | Longer-acting peptide |
Frequently Asked Questions
Research scientists frequently ask these questions when sourcing Ipamorelin:
What is Ipamorelin studied for?
Ipamorelin is studied in preclinical models for its selective effects on growth hormone secretion and neuroendocrine signaling. Research explores its potential metabolic and body composition effects in animal systems.
How does Ipamorelin differ from CJC-1295?
Ipamorelin is a pentapeptide GHS that works through ghrelin receptors, while CJC-1295 is a 30-amino-acid GHRH analog. Ipamorelin is more selective for growth hormone, whereas CJC-1295 has broader pituitary effects.
What is the mechanism of Ipamorelin?
Ipamorelin is a selective ghrelin receptor agonist that stimulates growth hormone secretion through GHS-R signaling on somatotroph cells. Research suggests it preferentially releases growth hormone while minimally affecting other hormones.
In what animal models is Ipamorelin studied?
Ipamorelin research employs rodent models, primates, and other animal systems to assess neuroendocrine effects, metabolic changes, and appetite signaling in controlled laboratory conditions.
What purity is required for research Ipamorelin?
Research-grade Ipamorelin from Core Research Peptides meets ≥99% purity standards with third-party testing certification. All supplies are for laboratory research use only.
How is Ipamorelin administered in research?
In preclinical protocols, Ipamorelin is administered subcutaneously, intramuscularly, or intravenously depending on the experimental design and tissue targets being studied.
Research Use Only Disclaimer
All peptides and compounds from Core Research Peptides are FOR RESEARCH USE ONLY. These materials are not intended for human consumption, therapeutic use, veterinary use, or any non-research application. All statements on this site are for informational and educational purposes in scientific research contexts only. The peptides and compounds discussed are studied exclusively in controlled laboratory settings and preclinical animal models. No medical, therapeutic, or health-related claims are made or implied. Users must comply with all local, state, and federal regulations regarding the purchase, possession, and use of research peptides and compounds. Core Research Peptides does not provide medical advice and assumes no liability for misuse or non-compliant applications.
Ready to Order?
Purchase research-grade Ipamorelin (≥99% pure, third-party tested) from Core Research Peptides:
All Core Research Peptides products are supplied for research use only in controlled laboratory environments. Compliance with all applicable regulations is the responsibility of the purchaser.
